2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- manufacturers
- NB-360
-
- $112.00
-
2026-07-27
- CAS:1262857-73-7
- Purity: 99.72%
- Supply Ability: 10g
- NB-360
-
- $112.00
-
2026-07-27
- CAS:1262857-73-7
- Purity: 99.72%
- Supply Ability: 10g
|
| | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- Basic information |
| Product Name: | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- | | Synonyms: | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl-;NB-360;CHS360;Inhibitor,BACE,NB 360,β-Secretase,inhibit,NB-360,NB360,Beta-secretase;NB-360, 10 mM in DMSO;N-(3-((3R,6R)-5-Amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-cyano-3-methylpicolinamide | | CAS: | 1262857-73-7 | | MF: | C21H19F4N5O2 | | MW: | 449.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1262857-73-7.mol | ![2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- Structure](CAS/20200331/GIF/1262857-73-7.gif) |
| | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (556.30 mM; Need ultrasonic) | | form | Solid | | color | White to off-white |
| | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- Usage And Synthesis |
| Uses | NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E[1][2]. | | References | [1] Neumann U, et al. Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8. DOI:10.1186/s13024-015-0033-8 [2] Neumann U, et al. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects. Br J Pharmacol. 2019 Sep;176(18):3435-3446. DOI:10.1111/bph.14582 |
| | 2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- Preparation Products And Raw materials |
|